Patents by Inventor Jonathan Schneck

Jonathan Schneck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120141482
    Abstract: Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.
    Type: Application
    Filed: February 9, 2012
    Publication date: June 7, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Publication number: 20110300168
    Abstract: This disclosure provides compositions and methods for inducing an immune response against influenza antigens, for example in elderly populations, as well as a sensitive artificial antigen presenting cell (aAPC) stimulation assay that can be used for expansion and analysis of multiple antigen specific T cell populations simultaneously.
    Type: Application
    Filed: May 3, 2011
    Publication date: December 8, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Schneck, Mathias Oelke
  • Publication number: 20110256147
    Abstract: Methods of diagnosis and treatment of malignant tumors, in particular ovarian tumors, using GD3 and GD3 inhibitors. Also provided are methods of modulating the immune system of a mammal by the administration of a GD3 and GD3 inhibitors.
    Type: Application
    Filed: December 1, 2009
    Publication date: October 20, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Mathias Oelke, Jonathan Schneck, Tonya Webb
  • Publication number: 20110243967
    Abstract: Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.
    Type: Application
    Filed: June 9, 2011
    Publication date: October 6, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Patent number: 7973137
    Abstract: Compositions comprising a cell in which a molecular complex with high affinity for its cognate ligand is bound to the surface of the cell are provided. To form the molecular complexes, extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection. Optionally, identical antigenic peptides can be bound to each ligand binding site of a molecular complex.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: July 5, 2011
    Assignee: Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Publication number: 20100008920
    Abstract: Platforms comprising at least one lymphocyte affecting molecule and at least one molecular complex that, when bound to an antigen, engages a unique clonotypic lymphocyte receptor can be used to induce and expand therapeutically useful numbers of specific lymphocyte populations. Antigen presenting platforms comprising a T cell affecting molecule and an antigen presenting complex can induce and expand antigen-specific T cells in the presence of relevant peptides, providing reproducible and economical methods for generating therapeutic numbers of such cells. Antibody inducing platforms comprising a B cell affecting molecule and a molecular complex that engages MHC-antigen complexes on a B cell surface can be used to induce and expand B cells that produce antibodies with particular specificities.
    Type: Application
    Filed: July 21, 2009
    Publication date: January 14, 2010
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Schneck, Mathias Oelke
  • Publication number: 20040204565
    Abstract: To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors.
    Type: Application
    Filed: April 5, 2004
    Publication date: October 14, 2004
    Applicant: The Johns Hopkins University
    Inventors: Jonathan Schneck, Drew Pardoll, Sean O'Herrin, Jill Slansky, Tim Greten
  • Publication number: 20040115216
    Abstract: Platforms comprising at least one lymphocyte affecting molecule and at least one molecular complex that, when bound to an antigen, engages a unique clonotypic lymphocyte receptor can be used to induce and expand therapeutically useful numbers of specific lymphocyte populations. Antigen presenting platforms comprising a T cell affecting molecule and an antigen presenting complex can induce and expand antigen-specific T cells in the presence of relevant peptides, providing reproducible and economical methods for generating therapeutic numbers of such cells. Antibody inducing platforms comprising a B cell affecting molecule and a molecular complex that engages MHC-antigen complexes on a B cell surface can be used to induce and expand B cells that produce antibodies with particular specificities.
    Type: Application
    Filed: July 14, 2003
    Publication date: June 17, 2004
    Applicant: The Johns Hopkins University
    Inventors: Jonathan Schneck, Mathias Oelke
  • Patent number: 6734013
    Abstract: To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors. pepMHC/Ig complexes are also useful in modulating effector functions of antigen-specific T cells. These pepMHC/Ig complexes are useful for studying TCR/MHC interactions and lymphocyte tracking and have uses as specific regulators of immune responses.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: May 11, 2004
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Drew Pardoll, Sean O'Herrin, Jill Slansky, Tim Greten
  • Patent number: 6458354
    Abstract: Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: October 1, 2002
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Publication number: 20020127231
    Abstract: Specificity in immune responses is in part controlled by the selective interaction of T cell receptors with their cognate ligands, peptide/MHC molecules. The discriminating nature of this interaction makes these molecules, in soluble form, good candidates for selectively regulating immune responses. Attempts to exploit soluble analogs of these proteins has been hampered by the intrinsic low avidity of these molecules for their ligands. To increase the avidity of soluble analogs for their cognates to biologically relevant levels, divalent peptide/MHC complexes or T cell receptors (superdimers) were constructed. Using a recombinant DNA strategy, DNA encoding either the MHC class II/peptide or TCR heterodimers was ligated to DNA coding for murine Ig heavy and light chains. These constructs were subsequently expressed in a baculovirus expression system.
    Type: Application
    Filed: September 18, 2001
    Publication date: September 12, 2002
    Inventors: Jonathan Schneck, Sean O'Herrin
  • Patent number: 6448071
    Abstract: Specificity in immune responses is in part controlled by the selective interaction of T cell receptors with their cognate ligands, peptide/MHC molecules. The discriminating nature of this interaction makes these molecules, in soluble form, good candidates for selectively regulating immune responses. Attempts to exploit soluble analogs of these proteins has been hampered by the intrinsic low avidity of these molecules for their ligands. To increase the avidity of soluble analogs for their cognates to biologically relevant levels, divalent peptide/MHC complexes or T cell receptors (superdimers) were constructed. Using a recombinant DNA strategy, DNA encoding either the MHC class II/peptide or TCR heterodimers was ligated to DNA coding for murine Ig heavy and light chains. These constructs were subsequently expressed in a baculovirus expression system.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: September 10, 2002
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin
  • Publication number: 20020006903
    Abstract: To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors.
    Type: Application
    Filed: February 22, 2001
    Publication date: January 17, 2002
    Inventors: Jonathan Schneck, Drew Pardoll, Sean O'Herrin, Jill Slansky, Tim Greten
  • Patent number: 6268411
    Abstract: To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors. pepMHC/Ig complexes are also useful in modulating effector functions of antigen-specific T cells. These pepMHC/Ig complexes are useful for studying TCR/MHC interactions and lymphocyte tracking and have uses as specific regulators of immune responses.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: July 31, 2001
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Drew Pardoll, Sean O'Herrin, Jill Slansky, Tim Greten
  • Patent number: 6140113
    Abstract: Polynucleotides encode soluble, multivalent molecular complexes which modify immune responses, and host cells comprise such polynucleotides. The molecular complexes comprise extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, which are covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: October 31, 2000
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Patent number: 6015884
    Abstract: Specificity in immune responses is in part controlled by the selective interaction of T cell receptors with their cognate ligands, peptide/MHC molecules. The discriminating nature of this interaction makes these molecules, in soluble form, good candidates for selectively regulating immune responses. Attempts to exploit soluble analogs of these proteins has been hampered by the intrinsic low avidity of these molecules for their ligands. To increase the avidity of soluble analogs for their cognates to biologically relevant levels, divalent peptide/MHC complexes or T cell receptors (superdimers) were constructed. Using a recombinant DNA strategy, DNA encoding either the MHC class II/peptide or TCR heterodimers was ligated to DNA coding for murine Ig heavy and light chains. These constructs were subsequently expressed in a baculovirus expression system.
    Type: Grant
    Filed: March 28, 1997
    Date of Patent: January 18, 2000
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin